Conditions: Alzheimer's Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 42
Healthy volunteers: yes

Brief summary:
This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 multiple doses, how the body handles the drug, and the drug's effect on the body.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: LY2886721 intervention 2: Placebo
Intervention descriptions: intervention 1: 5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days intervention 2: Administered orally as capsules, daily for 14 days

Protocol document: